Title | Management of CML-blast crisis. |
Publication Type | Journal Article |
Year of Publication | 2016 |
Authors | Hehlmann R, Saußele S, Voskanyan A, Silver RT |
Journal | Best Pract Res Clin Haematol |
Volume | 29 |
Issue | 3 |
Pagination | 295-307 |
Date Published | 2016 Sep |
ISSN | 1532-1924 |
Keywords | Allografts, Blast Crisis, Humans, Leukemia, Myelogenous, Chronic, BCR-ABL Positive, Mutation, Prognosis, Protein Kinase Inhibitors, Stem Cell Transplantation |
Abstract | Tyrosine kinase inhibitors (TKI) have moderately improved survival in BC, but a median survival of less than 1 year is still unsatisfactory. This article reviews the various tests required for diagnosis of BC, features at diagnosis, treatment modalities (intensive chemotherapy, TKI, Allo-SCT and a selection of investigational agents), options of prevention and predictors of progression. The best prognosis is observed in patients that achieve a 2nd CP. Allo-SCT probably further improves prognosis of patients in 2nd CP. The choice of TKI should be directed by the mutation profile of the patient. BC can be prevented. A careful analysis of risk factors for progression may help. Current treatment options are combined in a concluding strategy for the management of BC. |
DOI | 10.1016/j.beha.2016.10.005 |
Alternate Journal | Best Pract Res Clin Haematol |
PubMed ID | 27839570 |
Submitted by jaj2026 on October 27, 2017 - 4:21pm